Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data

Selected Quarterly Financial Data (Unaudited)

The following table presents selected quarterly financial data for the years ended December 31, 2014 and 2013.

	Three Months Ended
	Mar. 31, 2014			June 30, 2014			Sept. 30, 2014			Dec. 31, 2014			Mar. 31, 2013			June 30, 2013		Sept. 30, 2013		Dec. 31, 2013
				(4)						(3) (4)			(1)							(2)
	(In thousands, except per share data)
Net revenue	$	177,235		$	183,774		$	172,401		$	190,998		$	155,753		$	172,826	$	174,282	$	185,003
Cost of revenue	66,867			85,687			69,076			66,000			56,714			63,938		65,794		76,339
Total operating expenses	162,484			215,660			185,052			225,779			178,392			143,907		151,509		200,865
Net income (loss) attributable to The Medicines Company	(4,996		)	(5,157		)	(16,736		)	(5,323		)	(11,573		)	18,094		7,793		1,198
Basic net income per common share attributable to The Medicines Company	$	(0.08	)	$	(0.08	)	$	(0.26	)	$	(0.08	)	$	(0.21	)	$	0.33	$	0.13	$	0.02
Diluted net income per common share attributable to The Medicines Company	$	(0.08	)	$	(0.08	)	$	(0.26	)	$	(0.08	)	$	(0.21	)	$	0.30	$	0.12	$	0.02

(1) Net loss for the first quarter of 2013 includes licensing costs of $25.0 million for a transaction with Alnylam on the PCSK9 RNAi hypercholesterolemia program.

(2) Net income for the fourth quarter of 2013 includes a $10.9 million increase related to the progression in development work for IONSYS related to the Company’s Incline acquisition and a tax benefit of $13.6 million from reducing the Company’s deferred tax liabilities associated with the Incline acquisition. 

(3) In December 2014, the Company entered into a settlement and amendment to the merger agreement with Incline Therapeutics, Inc., which resulted in revisions to certain milestone triggers, a reduction in total milestone payments and the release of the escrow funds to the Company. As a result, net loss for the fourth quarter of 2014 includes $25.7 million in one-time income in connection with the settlement with the former equityholders of Incline related to the representations and warranties included in the merger agreement.

(4) Net loss for the second and fourth quarters of 2014 includes impairment charges on product licenses in the amount of $15.1 million and $6.4 million, respectively to cost of sales, as a result of reductions in estimated future cash flows expected to be generated by the acute care generic products as determined by an updated discount